

A1 4. (amended) An antibody fragment according [to any one of] Claim[s] 1 [to Claim 3] wherein each heavy chain is a V_H-CH1 chain terminally substituted by a hinge region domain.

6. (amended) An antibody fragment according to [any one of] Claim 1 [to Claim 5] wherein the polymer is an optionally [substituted] substituted straight or branched chain polymer selected from the group consisting of polyalkylene, polyalkenylene [or] and polyoxyalkylene [polymer], or a branched or unbranched polysaccharide.

A2 9719045 "120700 7. (amended) An antibody fragment according to Claim 6 wherein the polymer is an optionally substituted straight or branched chain polymer selected from the group consisting of poly(ethylene glycol) or a derivative [thereof] of poly(ethylene glycol).

8. (amended) An antibody fragment according to Claim 7 wherein the polymer is selected from the group consisting of methoxy(polyethylene glycol) or a derivative [thereof] of methoxy(polyethylene glycol).


A3 10. (amended) An antibody fragment according to [any one of the preceding claims] Claim 1 wherein each interchain bridge is the residue of a homo- or heterobifunctional cross-linking reagent.

12. (amended) An antibody fragment according to [any one of] Claim 1 [to Claim 11] which is covalently attached to one or more effector or reporter molecules.

A4 13. (amended) An [antibody] antibody fragment according [to any one of the preceding claims] Claim 1 which is able to selectively bind to a cell surface or soluble antigen.

In claim 15, line 3, replace "acceptable" with -- acceptable --.

Respectfully submitted,



Ellen M. Klann, Ph.D.
Registration No. 44,836

Date: 7 December 2000

Woodcock Washburn Kurtz
Mackiewicz and Norris LLP
One Liberty Place - 46th Floor,
Philadelphia, PA 19103,
(215) 557-5948

0919045-120700